Nasdaq Inc vs Novartis AG — how do they compare? Nasdaq Inc trades at $95.05 (market cap $53.11B), while Novartis AG trades at $152.85 (market cap $295.37B). The key difference: Novartis AG is far larger — about 5.6× Nasdaq Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NDAQ | NVS | |
|---|---|---|
Market Cap | $53.11B | $295.37B |
Sector | Financials | Health |
52-Week High | $100.98 | $168.62 |
52-Week Low | $76.85 | $119.31 |
Enterprise Value | $59.57B | $336.69B |
Dividend Yield | 1.22% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.62, up 1.09% today, with strong technical momentum and consistent earnings beats. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. The company announced the acquisition of LeveL Markets, advancing its always-on markets strategy, and maintains a bullish analyst consensus.
Outlook remains positive with a consensus price target of $109.20, offering ~14% upside. Risks include market volatility sensitivity and integration challenges from acquisitions. Solid profitability and strategic growth initiatives support a favorable investment case, though macroeconomic headwinds warrant monitoring.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →